Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.1% - Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price fell 1.1% during mid-day trading on Monday . The company traded as low as $4.83 and last traded at $4.98. 6,843,864 shares traded hands during trading, a decline of 56% from the average session volume of 15,388,591 shares. The stock had previously closed at $5.03.

Analyst Ratings Changes

Several brokerages have recently commented on RXRX. Needham & Company LLC reduced their price objective on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday, February 28th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Morgan Stanley dropped their price objective on shares of Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating on the stock in a report on Monday, June 16th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of "Hold" and a consensus price target of $7.00.

Recursion Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11. The company has a fifty day moving average price of $4.89 and a 200 day moving average price of $6.19. The stock has a market cap of $2.20 billion, a P/E ratio of -3.05 and a beta of 0.84.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The business had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.39) EPS. On average, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Private Trust Co. NA acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth about $27,000. AlphaQuest LLC bought a new stake in Recursion Pharmaceuticals during the 1st quarter worth approximately $36,000. GAMMA Investing LLC increased its holdings in Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after purchasing an additional 2,026 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after purchasing an additional 2,387 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.